Related Experiment Video

Updated: Jul 16, 2026

Isolation of Double Negative αβ T Cells from the Kidney
06:56

Isolation of Double Negative αβ T Cells from the Kidney

Published on: May 16, 2014

Neutralising antibodies against interferon beta in multiple sclerosis

Guido Antonelli

    Lancet (London, England)
    |January 17, 2004
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
    07:52

    Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

    Published on: September 10, 2018

    Humanized Mediator Release Assay as a Read-Out for Allergen Potency
    10:22

    Humanized Mediator Release Assay as a Read-Out for Allergen Potency

    Published on: June 29, 2021

    Related Experiment Videos

    Last Updated: Jul 16, 2026

    Isolation of Double Negative αβ T Cells from the Kidney
    06:56

    Isolation of Double Negative αβ T Cells from the Kidney

    Published on: May 16, 2014

    Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
    07:52

    Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

    Published on: September 10, 2018

    Humanized Mediator Release Assay as a Read-Out for Allergen Potency
    10:22

    Humanized Mediator Release Assay as a Read-Out for Allergen Potency

    Published on: June 29, 2021

    Related Concept Videos

    TGF - β Signaling Pathway01:16

    TGF - β Signaling Pathway

    The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...

    Articles linked to this work by shared authors, journal, and citation graph.

    TTV virome marks immune exhaustion, α7nAChR alteration, and mortality in elderly patients with severe COPD.

    GeroScience·2026

    Previous COVID-19 Vaccination Modulates Type I Interferon and Natural Killer Cell Responses During SARS-CoV-2 Infection.

    Journal of cellular and molecular medicine·2026

    Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study.

    Pediatric pulmonology·2026

    Analysis of Torquetenovirus DNA levels in NSCLC patients treated with immune checkpoint inhibitors.

    PloS one·2026

    In vitro evaluation of the novel antibiotic zosurabalpin against carbapenem-resistant Acinetobacter baumannii clinical isolates.

    Journal of global antimicrobial resistance·2026

    Monkeypox virus replication and host response in vaginal and ectocervical epithelial cells.

    Virulence·2026

    1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

    Lancet (London, England)·2026

    Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

    Lancet (London, England)·2026

    Advancing the relevance of clinical trials for older patients.

    Lancet (London, England)·2026

    Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

    Lancet (London, England)·2026

    Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

    Lancet (London, England)·2026

    Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

    Lancet (London, England)·2026

    Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.

    Case reports in dermatological medicine·2026

    Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.

    Frontiers in endocrinology·2026

    Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.

    Kidney diseases (Basel, Switzerland)·2026

    Diffuse Large B-cell Lymphoma Initially Managed As Secondary Immune Thrombocytopenia: A Case Report.

    Cureus·2026

    Adverse pregnancy outcome associations among women prior to a diagnosis of systemic lupus erythematosus.

    Frontiers in lupus·2026

    Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.

    Frontiers in cell and developmental biology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us